Azidomorphine and rymazolium an approach to the ideal analgesic

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

From a series of newly synthetized morphine derivatives 6-deoxy-6-azido-dihydroisomorphine /azido-morphine/ and 6-deoxy-6-azido-dihydroisocodeine /azido-codeine/ were selected for detailed pharmacological study. In the hot plate test in rats, azidomorphine proved to be about 300 times, azidocodeine about 13 times more potent than morphine. Administration of azidomorphine over a period of ten weeks proved it to be significantly less toxic in the rat than morphine. In the jumping test severe withdrawal symptoms could be precipitated in mice who received 40 times the analgesic ED50 dose /200 mg/kg/ of morphine. In contrast, only moderate dependence could be demonstrated with this test in mice who received 2800 times the analgesic ED50 dose of azidomorphine /70 mg/kg/. Treatment with increasing doses of morphine led to the development of high grade tolerance and physical dependence in rats and monkeys /Rhesus macacus/. Severe abstinence syndrome was precipitated following the administration of nalorphine in rats pretreated for 24 days with rapidly increasing doses of morphine. Severe abstinence symptoms were elicited in addicted monkeys on abrupt withdrawal of morphine on the 55th, 176th and 300th days of treatment. In parallel experiments no tolerance or physical dependence developed in rats or monkeys pretreated with increasing, equianalgesic doses of azidomorphine. Rymazolium /1,6-dimethyl1-3-carbethoxy-4-oxo-6,7,8,9, tetra-hydrohomopyrimidazole methylsulphate, Probon, MZ-144/ a new non-narcotic analgesic strongly potentiated the analgesic effect of azidomorphine and azidocodeine. On the basis of the reported animal experiments and preliminary clinical trials it is reasonable to expect that with the combined administration of azidomorphine or azidocodeine with Rymazolium it will be possible to obtain relief of severe, acute or chronic pain without significant risk of the development of addiction and/or tolerance.

Original languageEnglish
Pages (from-to)175-191
Number of pages17
JournalPharmacological Research Communications
Volume5
Issue number2
DOIs
Publication statusPublished - 1973

Fingerprint

Morphine
Analgesics
Haplorhini
Morphine Derivatives
Nalorphine
Non-Narcotic Analgesics
Codeine
Substance Withdrawal Syndrome
Poisons
Acute Pain
azidomorphine
Macaca mulatta
Chronic Pain
Clinical Trials
Pharmacology
Therapeutics
azidocodeine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Azidomorphine and rymazolium an approach to the ideal analgesic. / Knoll, J.

In: Pharmacological Research Communications, Vol. 5, No. 2, 1973, p. 175-191.

Research output: Contribution to journalArticle

@article{97cad4c99d0d4d9ab285251f99344f9e,
title = "Azidomorphine and rymazolium an approach to the ideal analgesic",
abstract = "From a series of newly synthetized morphine derivatives 6-deoxy-6-azido-dihydroisomorphine /azido-morphine/ and 6-deoxy-6-azido-dihydroisocodeine /azido-codeine/ were selected for detailed pharmacological study. In the hot plate test in rats, azidomorphine proved to be about 300 times, azidocodeine about 13 times more potent than morphine. Administration of azidomorphine over a period of ten weeks proved it to be significantly less toxic in the rat than morphine. In the jumping test severe withdrawal symptoms could be precipitated in mice who received 40 times the analgesic ED50 dose /200 mg/kg/ of morphine. In contrast, only moderate dependence could be demonstrated with this test in mice who received 2800 times the analgesic ED50 dose of azidomorphine /70 mg/kg/. Treatment with increasing doses of morphine led to the development of high grade tolerance and physical dependence in rats and monkeys /Rhesus macacus/. Severe abstinence syndrome was precipitated following the administration of nalorphine in rats pretreated for 24 days with rapidly increasing doses of morphine. Severe abstinence symptoms were elicited in addicted monkeys on abrupt withdrawal of morphine on the 55th, 176th and 300th days of treatment. In parallel experiments no tolerance or physical dependence developed in rats or monkeys pretreated with increasing, equianalgesic doses of azidomorphine. Rymazolium /1,6-dimethyl1-3-carbethoxy-4-oxo-6,7,8,9, tetra-hydrohomopyrimidazole methylsulphate, Probon, MZ-144/ a new non-narcotic analgesic strongly potentiated the analgesic effect of azidomorphine and azidocodeine. On the basis of the reported animal experiments and preliminary clinical trials it is reasonable to expect that with the combined administration of azidomorphine or azidocodeine with Rymazolium it will be possible to obtain relief of severe, acute or chronic pain without significant risk of the development of addiction and/or tolerance.",
author = "J. Knoll",
year = "1973",
doi = "10.1016/S0031-6989(73)80035-9",
language = "English",
volume = "5",
pages = "175--191",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Azidomorphine and rymazolium an approach to the ideal analgesic

AU - Knoll, J.

PY - 1973

Y1 - 1973

N2 - From a series of newly synthetized morphine derivatives 6-deoxy-6-azido-dihydroisomorphine /azido-morphine/ and 6-deoxy-6-azido-dihydroisocodeine /azido-codeine/ were selected for detailed pharmacological study. In the hot plate test in rats, azidomorphine proved to be about 300 times, azidocodeine about 13 times more potent than morphine. Administration of azidomorphine over a period of ten weeks proved it to be significantly less toxic in the rat than morphine. In the jumping test severe withdrawal symptoms could be precipitated in mice who received 40 times the analgesic ED50 dose /200 mg/kg/ of morphine. In contrast, only moderate dependence could be demonstrated with this test in mice who received 2800 times the analgesic ED50 dose of azidomorphine /70 mg/kg/. Treatment with increasing doses of morphine led to the development of high grade tolerance and physical dependence in rats and monkeys /Rhesus macacus/. Severe abstinence syndrome was precipitated following the administration of nalorphine in rats pretreated for 24 days with rapidly increasing doses of morphine. Severe abstinence symptoms were elicited in addicted monkeys on abrupt withdrawal of morphine on the 55th, 176th and 300th days of treatment. In parallel experiments no tolerance or physical dependence developed in rats or monkeys pretreated with increasing, equianalgesic doses of azidomorphine. Rymazolium /1,6-dimethyl1-3-carbethoxy-4-oxo-6,7,8,9, tetra-hydrohomopyrimidazole methylsulphate, Probon, MZ-144/ a new non-narcotic analgesic strongly potentiated the analgesic effect of azidomorphine and azidocodeine. On the basis of the reported animal experiments and preliminary clinical trials it is reasonable to expect that with the combined administration of azidomorphine or azidocodeine with Rymazolium it will be possible to obtain relief of severe, acute or chronic pain without significant risk of the development of addiction and/or tolerance.

AB - From a series of newly synthetized morphine derivatives 6-deoxy-6-azido-dihydroisomorphine /azido-morphine/ and 6-deoxy-6-azido-dihydroisocodeine /azido-codeine/ were selected for detailed pharmacological study. In the hot plate test in rats, azidomorphine proved to be about 300 times, azidocodeine about 13 times more potent than morphine. Administration of azidomorphine over a period of ten weeks proved it to be significantly less toxic in the rat than morphine. In the jumping test severe withdrawal symptoms could be precipitated in mice who received 40 times the analgesic ED50 dose /200 mg/kg/ of morphine. In contrast, only moderate dependence could be demonstrated with this test in mice who received 2800 times the analgesic ED50 dose of azidomorphine /70 mg/kg/. Treatment with increasing doses of morphine led to the development of high grade tolerance and physical dependence in rats and monkeys /Rhesus macacus/. Severe abstinence syndrome was precipitated following the administration of nalorphine in rats pretreated for 24 days with rapidly increasing doses of morphine. Severe abstinence symptoms were elicited in addicted monkeys on abrupt withdrawal of morphine on the 55th, 176th and 300th days of treatment. In parallel experiments no tolerance or physical dependence developed in rats or monkeys pretreated with increasing, equianalgesic doses of azidomorphine. Rymazolium /1,6-dimethyl1-3-carbethoxy-4-oxo-6,7,8,9, tetra-hydrohomopyrimidazole methylsulphate, Probon, MZ-144/ a new non-narcotic analgesic strongly potentiated the analgesic effect of azidomorphine and azidocodeine. On the basis of the reported animal experiments and preliminary clinical trials it is reasonable to expect that with the combined administration of azidomorphine or azidocodeine with Rymazolium it will be possible to obtain relief of severe, acute or chronic pain without significant risk of the development of addiction and/or tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0015782629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015782629&partnerID=8YFLogxK

U2 - 10.1016/S0031-6989(73)80035-9

DO - 10.1016/S0031-6989(73)80035-9

M3 - Article

AN - SCOPUS:0015782629

VL - 5

SP - 175

EP - 191

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -